Larger and more invasive colorectal carcinoma contains larger amounts of plasminogen activator inhibitor type 1 and its relative ratio over urokinase receptor correlates well with tumor size

Cancer

Volumn 86, Issue 12, 1999, Pages 2602-2611

  Abe, Jinro ^a   Urano, Tetsumei ^a   Konno, Hiroyuki ^a   Erhan, Yamaç ^b   Tanaka, Tatsuo ^a   Nishino, Nobuhiko ^a   Takada, Akikazu ^a   Nakamura, Satoshi ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b EGE UNIVERSITY   (Turkey)

Author keywords

Colorectal carcinoma; Plasminogen activator inhibitor type 1; Plasminogen activator inhibitor type 2.; Urokinase type plasminogen activator; Urokinase type plasminogen activator receptor

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; UROKINASE; UROKINASE RECEPTOR;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER SIZE; COLORECTAL CARCINOMA; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; LIVER METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; TUMOR GROWTH;

ADULT; AGED; CARCINOMA; COLORECTAL NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM STAGING; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RECEPTORS, CELL SURFACE; SURVIVAL ANALYSIS; URINARY PLASMINOGEN ACTIVATOR;

EID: 0033573059     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19991215)86:12<2602::AID-CNCR4>3.0.CO;2-S     Document Type: Article

References (57)

1. Dano K, Andreasen PA, Grondahl HJ, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 1985;44:139-266.
2. Blasi F, Vassalli JD, Dano K. Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors. J Cell Biol 1987;104:801-4.
3. Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991;64:327-36.
4. Pollanen J, Stephens RW, Vaheri A. Directed plasminogen activation at the surface of normal and malignant cells. Adv Cancer Res 1991;57:273-328.
5. Andreasen PA, Kjoller L, Christensen L, Duffy MJ. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 1997;72:1-22.
6. Duffy MJ. The role of proteolytic enzymes in cancer invasion and metastasis. Clin Exp Metast 1992;10:145-55.
7. Ossowski L, Reich E. Antibodies to plasminogen activator inhibit human tumor metastasis. Cell 1983;35:611-9.
8. Ossowski L. In vivo invasion of modified chorioallantoic membrane by tumor cells: the role of cell surface-bound urokinase. J Cell Biol 1988;107:2437-45.
9. Dano K, Behrendt N, Brunner N, Eliis V, Ploug M, Pyke C. The urokinase receptor. Protein structure and role in plasminogen activation and cancer invasion. Fibrinolysis 1994; 8(Suppl 1):189-203.
10. Ellis V, Dano K. Plasminogen activation by receptor-bound urokinase. Semin Thromb Hemost 1991;17:194-200.
11. Hasui Y, Suzumiya J, Marutsuka K, Sumiyoshi A, Hashida S, Ishikawa E. Comparative study of plasminogen activators in cancers and normal mucosae of human urinary bladder. Cancer Res 1989;49:1067-70.
12. Duffy MJ, Reilly D, O'Sullivan C, O'Higgins N, Fennelly JJ, Andreasen P. Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res 1990;50:6827-9.
13. Hasui Y, Marutsuka K, Suzumiya J, Kitada S, Osada Y, Sumiyoshi A. The content of urokinase-type plasminogen activator antigen as a prognostic factor in urinary bladder cancer. Int J Cancer 1992;50:871-3.
14. Foekens JA, Schmitt M, van Putten WL, Peters HA, Bontenbal M, Janicke F, et al. Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res 1992;52:6101-5.
15. Grondahl-Hansen J, Christensen IJ, Rosenquist C, Brunne N, Mouridsen HT, Dano K, et al. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 1993;53:2513-21.
16. Janicke F, Schmitt M, Pache L, Ulm K, Harbeck N, Hofler H, et al. Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat 1993;24:195-208.
17. Duffy MJ, Reilly D, McDermott E, O'Higgins N, Fennelly JJ, Andreasen PA. Urokinase plasminogen activator as a prognostic marker in different subgroups of patients with breast cancer. Cancer 1994;74:2276-80.
18. Bouchet C, Spyratos F, Martin PM, Hacene K, Gentile A, Oglobine J. Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas. Br J Cancer 1994;69:398-405.
19. Ganesh S, Sier CF, Griffioen G, Vloedgraven HJ, de Boer A, Welvaart K, et al. Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. Cancer Res 1994;54:4065-71.
20. Mulcahy HE, Duffy MJ, Gibbons D, McCarthy P, Parfrey NA, O'Donoghue DP, et al. Urokinase-type plasminogen activator and outcome in Dukes' B colorectal cancer. Lancet 1994; 344:583-4.
21. Nekarda H, Schmitt M, Ulm K, Wenninger A, Vogelsang H, Becker K, et al. Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res 1994;54:2900-7.
22. Pedersen H, Grondahl-Hansen J, Francis D, Osterlind K, Hansen HH, Dano K, et al. Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma. Cancer Res 1994;54:120-3.
23. Kobayashi H, Fujishiro S, Terao T. Impact of urokinase-type plasminogen activator and its inhibitor type 1 on prognosis in cervical cancer of the uterus. Cancer Res 1994;54:6539-48.
24. Cho JY, Chung HC, Noh SH, Roh JK, Min JS, Kim BS. High level of urokinase-type plasminogen activator is a new prognostic marker in patients with gastric carcinoma. Cancer 1997;79:878-83.
25. Bouchet C, Spyratos F, Hacene K, Durcos L, Becette V, Oglobine J. Prognostic value of urokinase plasminogen activator in primary breast carcinoma: comparison of two immunoassay methods. Br J Cancer 1998;77:1495-501.
26. Nekarda H, Schlegel P, Schmitt M, Stark M, Mueller JD, Fink U, et al. Strong prognostic impact of tumor-associated urokinase-type plasminogen activator in completely resected adenocarcinoma of the esophagus. Clin Cancer Res 1998;4:1755-63.
27. Kobayashi H, Ohi H, Shinohara H, Sugimura M, Fujii T, Terao T, et al. Saturation of tumour cell surface receptors for urokinase-type plasminogen activator by amino-terminal fragment and subsequent effect on reconstituted basement membranes invasion. Br J Cancer 1993;67:537-44.
28. Kobayashi H, Gotoh J, Fujie M, Shinohara H, Moniwa N, Terao T. Inhibition of metastasis of Lewis lung carcinoma by a synthetic peptide within growth factor-like domain of urokinase in the experimental and spontaneous metastasis model. Int J Cancer 1994;57:727-33.
29. Carrell RW, Owen MC. Plakalbumin, alpha 1-antitrypsin, antithrombin and the mechanism of inflammatory thrombosis. Nature 1985;317:730-2.
30. Sprengers ED, Kluft C. Plasminogen activator inhibitors. Blood 1987;69:381-7.
31. Kruithof EK. Plasminogen activator inhibitors - a review. Enzyme 1988;40:113-21.
32. Andreasen PA, Georg B, Lund LR, Riccio A, Stacey SN. Plasminogen activator inhibitors: hormonally regulated serpins. Mol Cell Endocrinol 1990;68:1-19.
33. Sumiyoshi K, Serizawa K, Urano T, Takada Y, Takada A, Baba S. Plasminogen activator system in human breast cancer. Int J Cancer 1992;50:345-8.
34. Nakamura M, Konno H, Tanaka T, Maruo Y, Nishino N, Aoki K, et al. Possible role of plasminogen activator inhibitor 2 in the prevention of the metastasis of gastric cancer tissues. Thromb Res 1992;65:709-19.
35. Nagayama M, Sato A, Hayakawa H, Urano T, Takada Y, Takada A. Plasminogen activators and their inhibitors in non-small cell lung cancer. Low content of type 2 plasminogen activator inhibitor associated with tumor dissemination. Cancer 1994;73:1398-405.
36. Morita S, Sato A, Hayakawa H, Ihara H, Urano T, Takada Y, et al. Cancer cells overexpress mRNA of urokinase-type plasminogen activator, its receptor and inhibitors in human non-small-cell lung cancer tissue: analysis by Northern blotting and in situ hybridization. Int J Cancer 1998;78:286-92.
37. Loskutoff DJ, Sawdey M, Mimuro J. Type 1 plasminogen activator inhibitor. Progr Hemost Thromb 1989;9:87-115.
38. Kruithof EK, Gudinchet A, Bachmann F. Plasminogen activator inhibitor 1 and plasminogen activator inhibitor 2 in various disease states. Thromb Haemost 1988;59:7-12.
39. Verspaget HW, Sier CF, Ganesh S, Griffioen G, Lamers CB. Prognostic value of plasminogen activators and their inhibitors in colorectal cancer. Eur J Cancer 1995;31A:1105-9.
40. Pedersen H, Brunner N, Francis D, Osterlind K, Ronne E, Hansen HH, et al. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res 1994;54:4671-5.
41. Chambers SK, Ivins CM, Carcangiu ML. Plasminogen activator inhibitor-1 is an independent poor prognostic factor for survival in advanced stage epithelial ovarian cancer patients. Int J Cancer 1998;79:449-54.
42. Bajou K, Noel A, Gerard RD, Massen V, Brunner N, Holst HC, et al. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med 1998; 4:923-8.
43. Deng G, Curriden SA, Wang S, Rosenberg S, Loskutoff DJ. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-media ted cell adhesion and release? J Cell Biol 1996;134:1563-71.
44. Stefansson S, Lawrence DA. The serpin PAI-1 inhibits cell migration by blocking integrinaVβ3 binding to vitronectin. Nature 1996;383:441-3.
45. Waltz DA, Natkin LR, Fujita RM, Wei Y, Chapman HA. Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin. J Clin Invest 1997;100: 58-67.
46. Duggan C, Maguire T, McDermott E, O'Higgins N, Fennelly JJ, Duffy MJ. Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer. Int J Cancer 1995;61:597-600.
47. Pedersen N, Schmitt M, Ronne E, Nicoletti MI, Hoyer HG, Conese M, et al. A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer. J Clin Invest 1993;92:2160-7.
48. Wei Y, Lukashev M, Simon DI, Bodary SC, Rosenberg S, Doyle MV, et al. Regulation of integrin function by the urokinase receptor. Science 1996;273:1551-5.
49. Preissner KT, May AE, Wohn KD, Germer M, Kanse SM. Molecular crosstalk between adhesion receptors and proteolytic cascades in vascular remodelling. Thromb Hemost 1997;78:88-95.
50. Kanse SM, Kost C, Wilhelm OG, Andreasen PA, Preissner KT. The urokinase receptor is a major vitronectin-binding protein on endothelial cells. Exp Cell Res 1996;224:344-53.
51. Ploug M, Kjalke M, Ronne E, Weidle U, Hoyer HG, Dano K. Localization of the disulfide bonds in the NH2-terminal domain of the cellular receptor for human urokinase-type plasminogen activator. A domain structure belonging to a novel superfamily of glycolipid-anchored membrane proteins. J Biol Chem 1993;268:17539-46.
52. Pyke C, Eriksen J, Solberg H, Nielsen BS, Kristensen P, Lund LR, et al. An alternatively spliced variant of mRNA for the human receptor for urokinase plasminogen activator. FEBS Lett 1993;326:69-74.
53. Sier CF, Stephens R, Bizik J, Mariani A, Bassan M, Pedersen N, et al. The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients. Cancer Res 1998;58:1843-9.
54. Stephens RW, Nielsen HJ, Christensen IJ, Thorlacius-Ussing O, Sorensen S, Dano K, et al. Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. J Natl Cancer Inst 1999;91:869-74.
55. Stephens RW, Pedersen AN, Nielsen HJ, Hamers MJ, Hoyer HG, Ronne E, et al. ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients. Clin Chem 1997;43:1868-76.
56. Ninomiya H, Hasegawa Y, Nagasawa T, Abe T. Excess soluble urokinase-type plasminogen activator receptor in the plasma of patients with paroxysmal nocturnal hemoglobinuria inhibits cell-associated fibrinolytic activity. Int J Hematol 1997;65:285-91.
57. Mizukami IF, Faulkner NE, Gyetko MR, Sitrin RG, Todd RF III. Enzyme-linked immunoabsorbent assay detection of a soluble form of urokinase plasminogen activator receptor in vivo. Blood 1995;86:203-11.